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Background and Purpose Patients with acute ischemic stroke, proximal vessel occlusion and a 
large ischemic core at presentation are commonly not considered for mechanical thrombectomy 
(MT). We tested the hypothesis that in patients with baseline large infarct cores, identification of 
remaining penumbral tissue using perfusion imaging would translate to better outcomes after 
MT.
Methods This was a multicenter, retrospective, core lab adjudicated, cohort study of adult 
patients with proximal vessel occlusion, a large ischemic core volume (diffusion weighted 
imaging volume ≥70 mL), with pre-treatment magnetic resonance imaging perfusion, treated 
with MT (2015 to 2018) or medical care alone (controls; before 2015). Primary outcome measure 
was 3-month favorable outcome (defined as a modified Rankin Scale of 0–3). Core perfusion 
mismatch ratio (CPMR) was defined as the volume of critically hypo-perfused tissue (Tmax >6 
seconds) divided by the core volume. Multivariable logistic regression models were used to 
determine factors that were independently associated with clinical outcomes. Outputs are 
displayed as adjusted odds ratio (aOR) and 95% confidence interval (CI).
Results A total of 172 patients were included (MT n=130; Control n=42; mean age 69.0±15.4 
years; 36% females). Mean core-volume and CPMR were 102.3±36.7 and 1.8±0.7 mL, 
respectively. As hypothesized, receiving MT was associated with increased probability of 
favorable outcome and functional independence, as CPMR increased, a difference becoming 
statistically significant above a mismatch-ratio of 1.72. Similarly, receiving MT was also 
associated with favorable outcome in the subgroup of 74 patients with CPMR >1.7 (aOR, 8.12; 
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Introduction
In recent years, mechanical thrombectomy (MT) has demon-
strated its compelling efficacy in reducing mortality and func-
tional dependence for patients with acute ischemic stroke (AIS) 
due to anterior proximal vessel occlusion (PVO).1,2 Patients with 
an unfavorable imaging profile at baseline, assessed using 
magnetic resonance imaging (MRI) diffusion weighted imaging 
(DWI) volume core (≥70 mL),1 or the computed tomography 
(CT)-based-Alberta Stroke Program Early CT score (ASPECTS) 
<6, were excluded in four of the seven randomized clinical tri-
als that validated MT in AIS-PVO,3 precluding to draw strong 
conclusions in this subgroup. Hence they are typically not of-
fered MT in clinical practice,1 despite converging evidence sug-
gesting a benefit of MT despite large ischemic core (LIC), with 
almost 25% of patients experiencing favorable functional out-
come after MT.3-9
Perfusion imaging is used in the diagnostic work up of AIS to 
identify hypo-perfused yet not infarcted (e.g., ‘at-risk’ or ‘sal-
vageable’) brain tissue,10 and to estimate the core perfusion 
mismatch ratio (CPMR).2 Nonetheless, perfusion data remain 
very scarce in patients with LIC before MT, while they are criti-
cally needed to pragmatically design future randomized trials, 
and better select patients for MT until then. 
We hypothesized that perfusion imaging may enhance the 
effective selection of AIS-PVO patients with LIC by determining 
those likeliest to benefit from revascularization and tested this 
hypothesis in a cohort study using data from a multicenter co-
hort, by comparing the rates of favorable functional outcome, 
symptomatic intracerebral hemorrhage (sICH), and case-fatali-
ty in patients with DWI assessed baseline LIC (>70 mL) and 
perfusion who received MT versus patients who were treated 
with intravenous thrombolysis only. The hypothesis driving this 
analysis was that in patients with baseline large infarct cores, 
identification of significant remaining penumbral tissue, as as-
sessed using CPMR, would translate to better outcomes after 
MT.
Methods
Study design 
The study was a multicenter, core-lab adjudicated, observa-
tional retrospective cohort study. The “Jeunes en Neuroradiolo-
gie Interventionnelle Research Collaborative” (JENI-RC), is a re-
cently launched trainee-led research network.11 Local JENI-RC 
members were asked to provide de-identified data for patients 
with DWI ASPECTs 0–6 otherwise meeting study inclusion cri-
teria (see below). Case report form items included demograph-
ics, relevant past medical history, sICH, and 3-month functional 
outcome. Imaging data were centralized by the internal core 
lab, for central assessment. Nine academic centers contributed 
data (eight in France, and one in Switzerland). This report was 
prepared according to the Strengthening the Reporting of Ob-
servational Studies in Epidemiology (STROBE) statement.12 
Ethics
As for all non-interventional retrospective studies of de-identi-
fied data in France, written informed consent was waived and 
a commitment to compliance (reference methodology CPMR-
3) was filed to the French National Information Science and 
Liberties Commission prior to data centralization, in respect to 
the General Data Protection Regulation.
Inclusion criteria
In the MT group, we included consecutive adult patients with 
AIS after 2015 if they had an occlusion of the intracranial in-
ternal carotid artery or of the M1 segment of the middle cere-
bral artery; had a large pretreatment ischemic core volume de-
fined as 70 mL or more on magnetic resonance-DWI as as-
sessed centrally; had no preexisting handicap as defined by a 
modified Rankin Scale (mRS) of 2 or higher; underwent MT; 
and if pre-treatment MR-T2* perfusion sequence had been 
performed. The control group was constituted by retrospective-
ly querying the prospective intravenous tissue plasminogen ac-
tivator (tPA) stroke data base at a single university hospital, to 
identify patients treated before MT related guidelines in 2015 
95% CI, 1.24 to 53.11; P=0.028). Overall (prior to stratification by CPMR) 73 (42.4%) patients 
had a favorable outcome at 3 months, with no difference amongst groups. 
Conclusions In patients currently deemed ineligible for MT due to large infarct ischemic cores at 
baseline, CPMR identifies a subgroup strongly benefiting from MT. Prospective studies are 
warranted.
Keywords Acute stroke; Ischemic stroke; Thrombectomy; Endovascular treatment; Perfusion 
imaging
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who met the same criteria but did not receive MT due to 
guidelines compliance.
Imaging analysis and mismatch definition
The post-processing and images interpretation were performed 
centrally after complete de-identification, by an internal core-
lab (B.K. and G.B.), blinded to clinical data. 
Ischemic core volumes (DWI volume) were calculated using 
Olea-Sphere version 3.0 software (Olea Medical, La Ciotat, 
France), by the semi-automated segmentation of brain tissue 
ipsilateral to the occlusion with apparent diffusion coefficient 
of 0.6×10-3 mm2/sec or less. Perfusion maps were generated 
using the Olea-Sphere version 3.0 software then used to calcu-
late critically hypo-perfused brain tissue, with an inferior 
threshold set, according to recent literature,13 at T max >6 sec-
onds. As in previous large studies investigating core penumbral 
mismatch,14,15 we defined penumbral tissue as the volume of 
critically hypo-perfused tissue minus the DWI volume. Similar-
ly, we defined the CPMR, as the volume of critically hypo-per-
fused tissue divided by the DWI volume, and defined a target 
mismatch as patients with a CPMR of 1.8 or above.
Assessment criteria
The primary endpoint was functional outcome assessed at 3 
months, using the mRS, with a favorable outcome defined by a 
score of 3 or less, taking into account the inherent severity of 
AIS with baseline LIC, and in line with recent literature. Sec-
ondary end points included functional independence defined as 
mRS of 0–2. Ninety days mortality, and the rate of symptom-
atic intracerebral hemorrhage within 7 days (according to Eu-
ropean Cooperative Acute Stroke Study [ECASS] II criteria).16 
Substantial reperfusion was defined as a modified Thrombolysis 
in Cerebral Infarction score of 2B, 2C, or 3.17 
Statistical analysis
Baseline characteristics of patients has been compared be-
tween MT group and control group. Continuous variables were 
summarized using mean±standard deviation or median (inter-
quartile range) where appropriate, and discrete variables were 
summarized using counts (percentages). Chi-square test, Fish-
er-exact test, t-test, Mann-Whitney test were used as appro-
priate for the univariate analysis, with a P<0.05 as the thresh-
old for statistical significance. 
Clinical outcomes were compared between MT group and 
control group. First, multivariable logistic regression models 
were used to determine factors that were independently asso-
ciated with clinical outcomes. Variables associated with the 
outcome in univariate analysis (P≤0.1) were entered into nomi-
nal logistic models, with a prespecified adjustment for age, in-
farct core, and CPMR. Backward elimination was then used to 
remove non-significant variables (P>0.05). The adjusted odds 
ratios (aOR) and 95% confidence interval (CI) of having favor-
able outcome (model 1) and functional independence (model 
2) were reported. Then, a sensitivity analysis was performed to 
assess for changes in the results in patients with a predefined 
CPMR cutoff of 1.8, as was reported in previous cornerstone 
studies analyzing the pertinence of CMPR in AIS-PVO pa-
tients.13,18 Finally, a shift analysis of mRS score (of 0–6 points) 
based on the proportional odds model has been performed. All 
analyses were done using JMP Pro 14 (Institute Inc., Cary, NC, 
USA) software. Where needed, we derived 95% CI by boot-
strapping (5,000 occurrences) statistical results.18 
Results
Study population
Between January 2015 and July 2018, in the MT group a total 
of 971 patients with AIS-PVO and ASPECTs 0–6 were screened 
for inclusion. After applying inclusion criteria, 168 patients 
were evaluated by the core lab, of which 130 were finally in-
cluded and analyzed in the MT group. Before 2015, a total of 
154 patients with DWI-ASPECTs 0–6 were screened for inclu-
sion in the control group, and 42 met study criteria (Figure 1). 
A total of 172 were finally included in the present analysis 
(36% females, mean age 69.0±15.4 years) (Table 1 for baseline 
clinical-imaging characteristics). Patients in the MT group were 
Figure 1. Flow chart. DWI, diffusion weighted imaging; ASPECTS, Alberta 
Stroke Program Early Computed Tomography Score; PWI, perfusion weight-
ed imaging; MT, mechanical thrombectomy.
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more frequently females (41% vs. 21%, P=0.03), less frequently 
received intravenous tPA (48.5% vs. 100%, P<0.01), were more 
frequently referred from an outside primary stroke center hos-
pital (25.4% vs. 0%, P<0.01), were younger (66.2±14.9 years-
old vs. 77.7±13.5, P<0.01). They did not differ otherwise in 
terms of baseline clinical parameters, notably for delay be-
tween onset and qualifying imaging (P=0.58) and occlusion 
site (P=0.82). Substantial recanalization was achieved in 
111/140 patients in the MT group (79.3%).
Core and penumbra
Mean core DWI volume was 102.3±36.7 mL and did not differ 
between groups. The volume of critically hypo-perfused tissue 
was larger in the MT group (mean 180.8±72.4 mL vs. 145.5±52.5 
mL, P<0.01), which consequently demonstrated larger penumbral 
volumes (mean 76.8±63.7 mL vs. 48.8ml±40.9 mL, P<0.01) as 
well as higher CPMRS (mean 1.8±0.7 vs. 1.5±0.5, P<0.01). A total 
of 90 (52%), 65 (38%), and 53 (31%) patients had CPMRS above 
1.6, 1.8, and 2.0 respectively (Supplementary Figure 1, in the sup-
plemental material for detailed CPMR distribution in the cohort).
Outcomes
Functional outcomes
At 3 months, 73 (42.4%) patients had a favorable functional 
outcome (mRS 0–3), with no difference amongst groups prior 
to stratification by CPMR (43.1% in the MT vs. 40.5, P=0.86). 
Forty-one patients (23.8%) were functionally independent and 
54 (31.4%) were deceased (P=1.000) (Table 2). Unfavorable 
outcome was associated with higher age, higher baseline NI-
HSS, history of hypertension, and diabetes mellitus (Supple-
mentary Table 1).
Independent of, as well as within, treatment groups both 
larger core and larger penumbral volumes were associated with 
Table 1. Baseline characteristics of included patients
Variable All (n=172) Control (n=42) MT (n=130) P 
Age (yr) 69.0±15.4 77.7±13.5 66.2±15 <0.001
Female sex 62 (36) 9 (21.4) 53 (40.8) 0.029
Dyslipidemia 69 (40.1) 18 (42.9) 51 (39.2) 0.718
Diabetes mellitus 26 (15.1) 7 (16.7) 19 (14.6) 0.811
Tobacco use (current or past) 56 (32.6) 14 (33.3) 42 (32.3) 1.000
Hypertension 97 (56.4) 24 (57.1) 73 (56.2) 1.000
NIHSS 18.5±4.5 18±5.1 18.7±4.2 0.435
Left sided stroke 75 (43.6) 16 (38.1) 59 (45.4) 0.476
iv tPA 105 (61) 42 (100) 63 (48.5) <0.001
Drip and ship 33 (19.2) 0 (0) 33 (25.4) <0.001
ICA occlusion 31 (18) 7 (16.7) 24 (18.5) 0.269
Delay till imaging (min) 161.3±129 152.7±108.5 164±135.2 0.583
Volume T max <6 sec (mL) 172.2±69.6 145.5±52.5 180.8±72.4 <0.001
Mismatch ratio 1.8±0.7 1.5±0.5 1.8±0.7 <0.001
Core volume (mL) 102.3±36.7 96.7±33 104±37.7 0.233
Values are presented as mean±standard deviation or number (%). 
MT, mechanical thrombectomy; NIHSS, National Institute of Health Stroke Scale; iv tPA, intravenous tissue plasminogen activator; ICA, internal carotid artery. 
Table 2. Outcome of included patients 
Variable All (n=172) Control (n=42) MT (n=130) P 
Substantial recanalization - - 111 (79.3)
90-day, mRS 0–2 41 (23.8) 11 (26.2) 30 (23.1) 0.684
90-day, mRS 0–3 73 (42.4) 17 (40.5) 56 (43.1) 0.857
90-day, mortality 54/172 (31.4) 13 (30.9) 41 (31.5) 1
sICH 31/161 (19.3) 5/35 (14.3) 26/126 (20.26) 0.483
Values are presented as number (%). 
MT, mechanical thrombectomy; mRS, modified Rankin Scale; sICH, symptomatic intra-cranial hemorrhage. 
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poor functional outcome in univariable analysis (185±67.9 mL 
in patients with mRS 4–6 vs. 154±68.4 mL in those with mRS 
0–3, P<0.01; and 76±59 vs. 67±60, P=0.04) (Figure 2).
In the entire population, there was no difference in favorable 
outcome between treatment groups (P=0.68) (Table 1). After 
adjusting for age, hypertension, diabetes, core volume, CPMR, 
delay to imaging, intravenous tPA before MT, and occlusion 
site, there was a significant interaction between MT effect and 
CPMR in both models (Model 1: aOR, 0.29; P=0.008; and Mod-
el 2: aOR, 0.4; P=0.047), indicating an increasing benefit of MT 
as CPMR increases (Table 3). In the same model, with mismatch 
ratio dichotomized as a nominal variable (below or above 1.8) 
the odds ratio of the interaction term between treatment arm 
and mismatch ratio (>1.8), was 0.42 (95% CI, 0 to 0,82; 
P=0.02). 
Analyzing the probability for favorable outcome in the fully 
adjusted model plotted against CPMR, we showed that receiv-
ing MT (vs. not receiving MT) was associated with increased 
probability of favorable outcome and functional independence, 
as CPMR increased, a difference becoming statistically signifi-
cant above a CPMR of 1.72 for favorable outcome, and above 
1.93 for functional independence (Figure 3). 
As a sensitivity analysis, when stratifying by CPMR; in the 
sample of 65 patients with a CPMR of 1.8 or above, after ad-
justing for group specific outcome predictors (age, core vol-
ume, intravenous tPA, and CPMR), receiving MT was associated 
with a significant increase in the rate of favorable outcome 
(aOR, 999; 95% CI, 999 to infinite). Similarly, in the subgroup 
of 74 patients for which CPMR exceeded 1.7 (42% of favorable 
outcome in the MT group vs. 20% in the control group, 
P=0.031; receiving MT was associated with a significantly in-
creased rate of favorable outcome) (aOR, 8.12; 95% CI, 1.24 to 
53.11, P=0.028). Using ordinal regression, receiving MT was as-
sociated with overall favorable shift in mRS distribution (com-
mon risk ratio, 1.83; 95% CI, 1.01 to 3.44; P=0.049) (Figure 4).
Finally, when restricting the sample to patients in the MT 
group, we found substantial recanalization to be associated 
with significantly higher odds of favorable outcome and of 3 
months functional independence, in fully adjusted models 
(aOR, 53.7; 95% CI, 5.0 to 573; P<0.001; and aOR infinite, 
P<0.001, respectively). Lower age (P<0.001), lower mismatch 
ratio (P=0.03), and lower core volume (P<0.001) were also as-
sociated with higher odds of favorable outcome, but the inter-
action between CPMR and substantial recanalization only 
tended towards significance (P=0.058).
Table 3. Multivariable models for outcome
Variable
For favorable outcome For functional independence
aOR 95% CI P aOR 95% CI P 
Age (yr) 0.95 0.92–0.98 <0.001 0.97 0.94–1.00 0.048
Diabetes 0.33 0.11–1.02 0.049 0.36 0.09–1.45 0.015
Hypertension 0.85 0.39–1.82 0.673 0.79 0.33–1.88 0.591
iv tPA 1.74 0.76–3.96 0.188 2.10 0.83–5.36 0.119
Delay till imaging (min) 1.00 1.00–1.00 0.934 1.00 1.00–1.00 0.754
ICA occlusion 0.75 0.28–2.00 0.572 0.59 0.18–1.94 0.391
Volume core (for each 10 mL) 0.79 0.69–0.89 <0.001 0.74 0.62–0.89 <0.001
Core perfusion mismatch (per unit) 0.19 0.06–0.56 <0.001 0.34 0.12–0.97 0.026
Received MT 1.95 0.62–6.07 0.248 1.64 0.48–5.58 0.426
Interaction mismatch group - - 0.009 - - 0.047
aOR, adjusted odds ratio; CI, confidence interval; iv tPA, intravenous tissue plasminogen activator; ICA, internal carotid artery; MT, mechanical thrombectomy.
Figure 2. Modified Rankin Scale at 3 months and initial diffusion weighted 
imaging (DWI) core volume and mismatch ratio per group. 
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Secondary outcomes
At 3 months, 54 patients were deceased (31.5% in the MT vs. 
30.9% in the control group, P=1). Fully adjusted model identi-
fied older age, larger core volume, higher CPMR, and diabetes 
mellitus as being associated with significantly higher mortality 
(all P<0.01) (Table 2). Treatment group did not influence 3 
months mortality rate (Supplementary Tables 2 and 3). 
A total of 31 of 161 patients with available data suffered 
from a sICH (20.6% in the MT group vs. 14.3%, P=0.48) (Table 
2). In our sample, receiving MT was not associated with higher 
odds of sICH (aOR, 1.94; 95% CI, 0.6 to 6.26; P=0.26). While 
larger infarct core was associated with more frequent sICH 
(aOR, 1.01 for each mL increase in core volume; 95% CI, 1 to 
1.03; P=0.02), higher CPMR was not (Supplementary Tables 4 
and 5). In the MT group, substantial recanalization was not as-
sociated with decreased odds of sICH (P=0.49).
Discussion
In this multicenter collaborative study we showed that (1) MT is 
strongly beneficial on clinical outcome of patients with large in-
farct core at baseline, and persisting core/penumbral mismatch 
(CPMR >1.72 in our sample and by extension >1.8), with no het-
erogeneity in treatment effect across strata of CPMR and (2) 
that MT does not increase the odds of sICH and mortality. 
The question of the best treatment approach for AIS-PVO 
patients with large infarct at baseline remains unanswered, 
despite being amongst the most timely and relevant in acute 
stroke care. There is indeed a critical need to assess treatment 
opportunities expansion to those patients that were excluded 
from princeps MT trials (especially patients with LIC, that are 
at critical risk of poor functional outcomes and for which 
guidelines remain ambiguous), and may in turn not be offered 
MT, despite a potential benefit. Until the results of dedicated 
trials such as Exploration of the limits of mechanical throm-
bectomy indications in a single action–Large Stroke Therapy 
Evaluation (IN EXTREMIS–LASTE) or Efficacy and Safety of 
Thrombectomy in Stroke With Extended Lesion and Extended 
Time Window (TENSION) become available, the community 
faces a challenge in the treatment strategy for this subgroup.
Expectedly, our results are in line with previous studies3,4,7,19-21 
demonstrating the direct correlation between larger infarct core 
sizes decreased odds of favorable functional outcome. In our 
sample as a whole, for every 10 mL increase in core volume, 
there was a 22% increase in the risk of unfavorable outcome, 
and a 26% increase in the risk of 90 days functional dependence. 
Our results, in that sense, confirm that presenting with a large 
infarct at baseline is of poorer prognosis and do support careful 
expectations’ management with families and caregivers. 
Less intuitively, but substantiating our working hypothesis, in-
creasing CPMR was also associated with lower chance of favor-
Figure 3. Probability of favourable functional outcome (A) or functional in-
dependence (B) by mismatch ratio, in patient receiving mechanical throm-
bectomy (yellow), and in the control group (blue).
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able outcome, with an odd decrease of 81% for every mismatch 
unit increase. This finding was not unexpected, since patients with 
higher CPMRS are at inherent higher risk for infarct progression 
within the hypo-perfused area, until recanalization or if recanali-
zation doesn’t occur, or not fast enough. In our sample, the benefit 
of MT over the control group became significant above a CPMR of 
1.72 corresponding to a minimal penumbral volume of 50.4 mL 
(e.g., if the patient has a core volume of exactly 70 mL) and was 
stable in the stratified subgroup of patients with CPMRS above 
1.7. Although the conceptual framework supporting the benefit of 
MT in patients with PVO and target mismatch has been substanti-
ated by a large number of publications, including the cornerstone 
studies from the diffusion and perfusion imaging evaluation for 
understanding stroke evolution (DEFUSE) group,13,22 there is still 
limited dedicated studies in the specific subgroup of patients with 
larger infarcts at baseline. Rebello et al.5 demonstrated in a sample 
of 24 patients with large infarct cores assessed using CT perfusion 
(cerebral blood flow <30%; 70 mL) and an penumbra volumes 
(Tmax >6 seconds) above 40 to 50 mL that MT was associated 
with significant reduction in final infarct volumes (110±65 mL vs. 
319±147 mL, P<0.001) but only a nonsignificant improvement in 
the overall distribution of mRS scores favoring the treatment 
group (P=0.18). These neutral results with regards to clinical out-
come, are likely due to insufficient power, in this subgroup limited 
by a binary design that excluded patients with limited mismatch, 
precluding to further test interaction between MT effects and 
CPMR. More recently, Campbell et al.15 showed in post hoc analy-
ses of individual patient level data from The Highly Effective 
Reperfusion evaluated in Multiple Endovascular Stroke Trials (HER-
MES) collaboration, that amongst the 583 patients with computed 
tomography perfusion (CTP), the interaction between CPMR and 
endovascular treatment effect was not significant (P=0.15), but 
statistical power was strongly limited by the small number of pa-
tients not meeting criteria (less than 5% with a CPMR <1.8 
amongst the 583 patients with CTP). In this study, CTP mismatch 
volume was negatively associated, in univariate analysis, with 
functional improvement (common odds ratio per 10 mL 0.96; 95% 
CI, 0.93 to 0.99; P=0.009) reinforcing the conceptual balance par-
adox by which larger mismatch volumes are associated with de-
creased favorable outcomes due to increased possibilities of infarct 
progression, and in turn explaining the increasing benefit of MT as 
CPMR increases, a notion that had not been confirmed before our 
study in patients with larger infarct cores. 
In secondary analyses, we did not show a significant associa-
tion between MT and the risk of sICH, and there was conversely 
a positive interaction between infarct core volume and treat-
ment group, in favor of MT. There’s been several reports on the 
risk of sICH after MT in LIC, none of which showed an increase in 
the risk of sICH after MT except in the HERMES collaboration3 
where, for patients with ASPECTS 0–4, sICH was more frequent 
in the MT group, although not significantly (adjusted cOR, 3.94; 
95% CI, 0.94 to 16.49; P interaction=0.025), and not reproduced 
when restricting the sample to patients with DWI volume ≥70 
mL were no significant difference of sICH between EVT (1/23, 
4.3%) and best medical treatment (2/37, 5.4%) was found.3,15 Of 
critical note, the most important predictor of sICH and paren-
chymal hemorrhage is core volume, independent of treatment 
modality,3,7,19,20,23 likely explaining that successful reperfusion was 
associated with lower sICH in many “real life” recent studies.7,19,20 
Whether the benefits of not revascularizing a patient to prevent 
sICH, outweigh those of revascularization to prevent infarction 
extension is unknown, but very unlikely, especially in patients 
with important mismatch, at highest risk for infarct progression 
and progression to malignant infarction. Our study was neither 
powered nor designed to answer this question.
There’s a long ongoing debate on optimal imaging modality 
(CT or MRI) for AIS-PVO patients’ selection for revascularization 
strategies.24-26 The main risk of patients’ selection in the context 
of AIS is over-selection, that is, to decline a patient a treatment 
that may have been beneficial. For patients with LIC, the ques-
tion of over-selection is amongst the timeliest in modern stroke 
care. The first level of over-selection may happen at the core as-
sessment level (e.g., dismissing a patient because of large in-
farct). Interestingly, in the HERMES collaboration,3 the treatment 
benefit in patients with ASPECTs 0–4 derived from the aggrega-
tion of CT and MRI ASPECTs data, and was likely contingent on 
the disproportionately larger effect size seen in the MRI sub-
group (aOR, 3.57; 95% CI, 1.22 to 10.39 vs. aOR, 1.68; 95% CI, 
0.58 to 4.87 in the CT group). Similarly, Campbell et al.15 demon-
strated that CTP was associated with significantly halved propor-
tion of patients functional independence (OR, 0.47; 95% CI, 0.30 
to 0.72; P=0.0007), and also with less functional improvement 
(cOR, 0.51; 95% CI, 0.36 to 0.72; P=0.0001) when compared to 
MRI, both studies reinforcing the notion that MRI may better se-
lect patients for MT, but at the inherent risk of overselecting. In 
that sense, our study provides critical answers with regards to 
outcome in patients with LIC by the use of MRI with known 
higher conspicuity and reproducibility to detect and measure in-
farct core when compared to CT (especially when ASPECTs is 
used).27 The second level of over-selection, accounting that pa-
tients are considered for MT even with a LIC, is perfusion imag-
ing. Our study showed, using strict post processing method, that 
patients with a CPMR above 1.72 (and by extension, over 1.8) 
demonstrated more favorable outcomes when treated with MT 
but the benefit increase was expectedly linear and not sudden at 
a discrete threshold of 1.72. While this finding suggests that pa-
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tients with lower CPMR are likely to also benefit from MT, more 
subjects would be needed to demonstrate it, the benefit would 
likely be lesser, and this would need to be confirmed in a larger 
scale study. Importantly, we did not demonstrate any harm de-
rived from MT in patients with lower CPMR. 
Altogether, by comforting patho-physiologically plausible and 
statistically stable answers the question of the benefit of MT in 
patients with LIC at baseline and persisting salvageable tissue, 
our study raises ethical and philosophical considerations. There is 
growing evidence that by withholding MT by fear of potential 
harm for some patients, we may actually dismiss a much larger 
of patients that may have benefited from revascularization. In 
that sense, by demonstrating the continuum of unfavorable out-
come paralleling the increases in core as well as mismatch vol-
umes, and by showing the increasing benefit of MT with increas-
ing CPMR, we actually fuel the argument that perfusion imaging 
is not needed as it may delay revascularization in eligible pa-
tients (and be used to decline MT to patients with CPMRS in the 
lower ranges, despite potential benefit). With no evidence of 
harm from MT in any of the explored configurations in our sam-
ple and the above-mentioned continuums in treatment benefit 
increases, it may be reasonable not to withhold treatment based 
on strict-cut offs (e.g., the study specific 1.72, applicable only to 
our sample, or the more common 1.8), but to adjust treatment 
decisions to both outcome and patients/families’ centered ex-
pectations. Results from future trials may yield more definite an-
swers to these questions, although the authors are not aware of 
any ongoing large randomized study using perfusion imaging as 
a selection criterion in patients with LIC. 
Our study has limitations, most inherent to its design. It was 
a retrospective analysis, with a high risk of selection bias in in-
cluded cases and important number of excluded cases due to 
the limited penetration of perfusion imaging for AIS amongst 
French centers and to the yet unusual use of MT in patients 
with LIC. For similar reasons, our sample size did not allow for 
a split into a derivation and a validation cohort, but we aimed 
at substantiating our estimates by various sensitivity analyses, 
which proved to be stable. We acknowledge that our control 
group was biased, by the fact that it included only patients 
who received intravenous tPA, and that this bias may have 
yielded underestimated estimates of the benefit of MT over 
best medical management. Lastly, using CPMR instead of CT 
allowed for more precise estimates of ischemic infarct cores, 
but make our results less generalizable beyond the pathophysi-
ological rationale it provides. 
Conclusions
In patients currently deemed ineligible for MT due to large in-
farct ischemic cores at baseline, CPMR identifies patients 
strongly benefiting from MT. These finding provide a data-driv-
en framework supporting both the relevance of CPMR perfu-
sion assessment at the acute phase of AIS due to PVO in pa-
tients with LIC, and the notion that there is no strict plausible 
cutoff in core or penumbral volumes above or below which MT 
may become harmful by comparison to best medical treatment 
alone. Our results may help at informing the design of future 
randomized trials and may, further, help inform clinical practice 
for more individualized decision making in this subgroup until 
higher level evidence becomes available.
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Supplementary Table 1. Univariate analysis of outcome predictors (mRS 0–3)
Variable Unfavorable (n=99) Favorable (n=73) P
Age (yr) 72.9±14.2 63.8±15.5 <0.001
Female sex 36 (36.4) 26 (35.6) 1
Dyslipidemia 49 (49.5) 20 (27.4) 0.003
Diabetes mellitus 20 (20.2) 6 (8.2) 0.005
Tobacco use (current or past) 28 (28.3) 28 (38.4) 0.187
Hypertension 65 (65.7) 32 (43.8) 0.005
NIHSS 19.3±4.5 17.5±4.3 0.011
Left sided stroke 46 (46.5) 29 (39.7) 0.355
iv tPA 56 (56.6) 49 (67.1) 0.205
Drip and ship 22 (22.2) 11 (15.1) 0.327
ICA occlusion 21 (21.2) 11 (15.1) 0.329
Delay till imaging (min) 167.3±137.9 153.1±116.4 0.468
Volume T max <6 sec (mL) 185.1±68 154.7±68.4 0.004
Mismatch ratio 1.8±0.7 1.7±0.6 0.166
Core volume (mL) 108.4±41.7 94±26.6 <0.001
Received MT 74 (74.7) 56 (76.7) 0.851
Values are presented as mean±standard deviation or number (%). 
mRS, modified Rankin Scale; NIHSS, National Institute of Health Stroke Scale; iv tPA, intravenous tissue plasminogen activator; ICA, internal carotid artery; 
MT, mechanical thrombectomy.
Supplementary Table 2. Univariable analysis of 90-day mortality
Variable Dead (n= 54) Alive (n=118) P
Age (yr) 77.63±11.99 65.09±15.21 <0.001
Female sex 19 (35.2) 43 (36.4) 1
Dyslipidemia 27 (50) 42 (35.6) 0.094
Diabetes 15 (27.8) 11 (9.3) 0.003
Hypertension 37 (68.5) 60 (50.8) 0.033
NIHSS 19.78±4.7 17.96±4.25 0.019
Tobacco use 11 (20.4) 45 (38.1) 0.023
ICA occlusion 10 (18.5) 22 (18.6) 1.000
Delay till imaging (min) 164.87±155.96 159.61±115.33 0.825
Drip and ship 12 (22.2) 21 (17.8) 0.534
iv tPA 30 (55.6) 75 (63.6) 0.401
Volume core (mL) 111.3±43.4 98.11±32.49 0.025
Volume T max >6 sec (min) 192.02±64.11 163.13±70.38 0.009
Mismatch ratio 1.86±0.75 1.7±0.65 0.173
MT 41 (31.5) 89 (68.5) vs. control, 1.000
Control 13 (30.9) 29 (69.1)
Values are presented as number (%) or mean±standard deviation. 
NIHSS, National Institute of Health Stroke Scale; ICA, internal carotid artery; iv tPA, intravenous tissue plasminogen activator; MT, mechanical thrombectomy.
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Supplementary Table 3. Multivariable model of 90-day mortality predictors (pre specified adjustment for core volume, mismatch ratio, and treatment group)
Variable aOR 95% CI P
Age 1.11 1.07–1.16 <0.001
Diabetes 4.34 1.54–12.27 0.006
Volume core (each 10 mL) 1.32 1.16–1.53 <0.001
Core perfusion mismatch 2.38 1.26–4.47 0.006
MT vs. Control 0.49 0.19–1.37 0.177
aOR, adjusted odds ratio; CI, confidence interval; MT, mechanical thrombectomy.
Supplementary Table 4. Univariable analysis of sICH (ECASS II) predictors
Variable sICH (n=31) No sICH (n=130) P
Age (yr) 72.89±12.15 67.74±15.98 0.051
Female sex 9 (29.0) 50 (38.5) 0.409
Dyslipidemia 12 (38.7) 51 (39.2) 1.000
Diabetes mellitus 9 (29.0) 14 (10.8) 0.002
Hypertension 22 (71.0) 67 (51.5) 0.068
NIHSS 18.53±3.46 18.6±4.67 0.925
Tobacco use 6 (19.4) 45 (34.6) 0.133
ICA occlusion 7 (22.6) 22 (16.9) 0.444
Delay till imaging (min) 149.71±113.66 163.7±131.43 0.548
Drip and ship 7 (22.6) 24 (18.5) 0.609
iv tPA 19 (61.3) 78 (60.0) 1.000
Volume core (mL) 112.43±38.47 100.6±35.67 0.126
Volume T max >6 sec (mL) 188.75±59.87 171.58±72.5 0.175
Mismatch ratio 1.8±0.72 1.76±0.7 0.795
MT (P for vs. control) 26 (20.6) 100 (76.4) 0.475
Control 5 (14.3) 30 (85.7)
Values are presented as number (%) or mean±standard deviation. 
sICH, symptomatic intracerebral hemorrhage; ECASS, European Cooperative Acute Stroke Study; NIHSS, National Institute of Health Stroke Scale; ICA, internal 
carotid artery; iv tPA, intravenous tissue plasminogen activator; MT, mechanical thrombectomy.
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Supplementary Table 5. Multivariable model of symptomatic intra-cranial hemorrhage predictors (pre specified adjustment for core volume, mismatch ratio 
and treatment group)
Variable aOR 95% CI P
Age (yr) 1.03 1.00–1.07 0.051
Hypertension 1.15 0.43–3.03 0.77
Diabetes 3.58 1.21–10.64 0.02
Volume core (each 10 mL) 1.01 1.00–1.03 0.02
Core perfusion mismatch 1.29 0.68–2.46 0.43
MT vs. Control 1.94 0.59–6.26 0.26
aOR, adjusted odds ratio; CI, confidence interval; MT, mechanical thrombectomy. 
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Supplementary Figure 1. Distribution of core perfusion mismatch ratios 
(CPMRs) in the entire sample (A) and proportion of patients with CPMRs 
above 1.6, 1.8, and 2 (B).
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